Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $21.2 million.

  • Neurogene's Shares Outstanding (Diluted Average) rose 2486.21% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 2486.21%. This contributed to the annual value of $17.6 million for FY2024, which is 27722.31% up from last year.
  • Per Neurogene's latest filing, its Shares Outstanding (Diluted Average) stood at $21.2 million for Q3 2025, which was up 2486.21% from $21.1 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Shares Outstanding (Diluted Average) registered a high of $21.2 million during Q3 2025, and its lowest value of $433623.0 during Q1 2023.
  • For the 3-year period, Neurogene's Shares Outstanding (Diluted Average) averaged around $12.5 million, with its median value being $16.9 million (2024).
  • In the last 5 years, Neurogene's Shares Outstanding (Diluted Average) soared by 379825.61% in 2024 and then skyrocketed by 2421.09% in 2025.
  • Neurogene's Shares Outstanding (Diluted Average) (Quarter) stood at $4.7 million in 2023, then surged by 277.22% to $17.6 million in 2024, then rose by 20.5% to $21.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $21.2 million for Q3 2025, versus $21.1 million for Q2 2025 and $21.0 million for Q1 2025.